Related Experiment Video

Updated: May 28, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents

Evisabel A Craig1, Vladimir S Spiegelman

  • 1Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Pigment Cell & Melanoma Research
|October 11, 2011
PubMed

Insights

High levels of coding region determinant binding protein (CRD-BP) in melanoma cells promote chemotherapy resistance. Reducing CRD-BP enhances anti-cancer drug effectiveness by increasing apoptosis and slowing tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Malignant melanomas exhibit elevated levels of the mRNA binding protein, coding region determinant binding protein (CRD-BP).
  • CRD-BP is implicated in activating anti-apoptotic pathways, which can lead to therapeutic resistance.
  • The specific role of CRD-BP in melanoma chemoresistance remains largely uncharacterized.

Purpose of the Study:

  • To investigate the role of CRD-BP in conferring resistance to chemotherapy in melanoma.
  • To determine if targeting CRD-BP can enhance the efficacy of standard chemotherapeutic agents against melanoma.

Main Methods:

  • Utilized short hairpin RNA (sh-RNA) to knockdown CRD-BP expression in primary and metastatic melanoma cell lines.
  • Assessed the impact of CRD-BP knockdown on melanoma cell response to dacarbazine, temozolomide, vinblastine, and etoposide.
  • Investigated the downstream effects of CRD-BP inhibition on apoptosis, cell growth, and microphthalmia-associated transcription factor (MITF) expression.

Main Results:

  • CRD-BP knockdown significantly enhanced the sensitivity of melanoma cells to multiple chemotherapeutic agents.
  • Down-regulation of CRD-BP led to increased apoptosis and reduced melanoma cell proliferation in response to treatment.
  • Inhibition of CRD-BP decreased MITF expression, and its reintroduction partially restored CRD-BP function.

Conclusions:

  • High CRD-BP expression in melanoma cells contributes to resistance against chemotherapy.
  • Targeting CRD-BP represents a potential strategy to overcome chemoresistance in melanoma.
  • The observed chemoresistance mediated by CRD-BP appears to involve the regulation of MITF.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...